Professional Documents
Culture Documents
GBS 23
GBS 23
Guillain-Barr6 syndrome
A case-control study
B.C. Jacobs, MD, PhD; P.H. Rothbarth, MD, PhD; F.G.A. van der Meche, MD, PhD; P. Herbrink, PhD;
P.I.M. Schmitz, PhD; M.A. de Klerk; and P.A. van Doorn, MD, PhD
Article a b s t r a c t 4 b j e c t i u e : To determine which antecedent infections are specifically associated with the Guillain-Barre
syndrome (GBS). Background: Infections with many agents have been reported preceding GBS. Some infections are
related to specific clinical and immunologic subgroups in GBS. Most agents were reported in case reports and uncontrolled
small series of GBS patients only, and their relation to GBS and its subgroups remains unclear. Method: A serologic study
for 16 infectious agents in 154 GBS patients and 154 sex- and age-matched controls with other neurologic diseases. Acute
phase, pretreatment samples were used from clinically well-defined GBS patients. The seasonal distribution of serum
sampling in the GBS and control group was the same. Results: Multivariate analysis showed that in GBS patients,
infections with Campylobacter jejuni (32%),cytomegalovirus ( 13%), and Epstein-Barr virus (10%)were significantly more
frequent than in controls. Mycoplasma pneumoniae infections occurred more often in GBS patients (5%) than in controls
in univariate analysis. Infections with Huemophilus influenzae ( l % ) , parainfluenza 1 virus (l%), influenza A virus (l%),
influenza B virus (1961, adenovirus (1%),herpes simplex virus (l%),and varicella zoster virus (1%)were also demonstrated
in GBS patients, but not more frequently than in controls. C. jejuni infections were associated with antibodies to the
gangliosides GM1 and GDlb and with a severe pure motor form of GBS. Cytomegalovirus infections were associated with
antibodies to the ganglioside GM2 and with severe motor sensory deficits. Other infections were not related to specific
antiganglioside antibodies and neurologic patterns. Conclusions: Recent infections with C. jejuni, cytomegalovirus,
Epstein-Barr virus, and M. pneumoniae are specifically related to GBS. The variety of infections may contribute to the
clinical and immunologic heterogeneity of GBS.
NEUROLOGY 1998;51~1110-1115
The Guillain-Barre syndrome (GBS) is an acute poly- distinct clinical variants of GBS. The variety of re-
neuropathy that may lead to a variety of motor and ported infectious agents in GBS may therefore underlie
sensory deficits. It is considered a postinfectious dis- the immunologic and clinical heterogeneity in GBS.
Controversy exists over whether infections with
Downloaded from https://www.neurology.org by Kasturba Medical College - MAHE on 4 April 2024
we used serum samples from 154 sex- and age ( 2 4 year)- infectious agent was also estimated using a multivariate
matched control patients with other neurologic diseases conditional logit model for matched case-control data, with
(OND) than GBS. The controls resided in the southwest disease status (GBS or control) as dependent variable and
area of The Netherlands and were referred to the Univer- the infectious agents as independent variables.16 With re-
sity Hospital Rotterdam in the period from 1990 to 1996. spect to the clinical features of GBS patients, differences in
The population in this area reflects that of other parts in proportions were tested with the chi-square test without
The Netherlands with respect to relevant demographic continuity correction or Fisher’s exact test, and differences
characteristics, such as urbanization ratio. The time of in medians with the Wilcoxon-Mann-Whitney U test. The
serum sampling in the control group and the group of GBS time for patients to reach independent locomotion was an-
patients had the same seasonal distribution. The OND alyzed by the Kaplan-Meier method and the log-rank test.
controls had chronic inflammatory demyelinating polyneu- All calculations were performed using STATA 5.0 for
ropathy (CIDP) (n = 21), other forms of neuropathy (n = Windows 95 (Stata Statistical Software, Release 5.0, Col-
60), MS (n = 41), cerebrovascular accidents (n = 141, mo- lege Station, TX).A p value < 0.05 was considered to be
tor neuron disease (n = 6)) MG (n = 6), or ot,her neurologic significant.
disorders (n = 6). All samples were obtained at admission
to the hospital and before treatment. In addition, serum Results. Infections and antecedent illness in GBS pa-
samples from 50 healthy subjects were tested. tients. In the 4 weeks preceding GBS, 105 (68%) of the
Znfection serology. Serum samples from GBS patients 154 patients reported some form of infectious illness, as
were tested to determine recent infections with 16 viruses indicated by their clinical symptoms. The most common
or bacteria frequently reported in GBS. The assays were identified cause of recent infections in patients with GBS
performed according to routine techniques with previously was C. jejuni (32%)(table 1).Other recent infections in
established criteria for positivity. C. jejuni infections were GBS patients were CMV (13%), EBV (lo%), M. pneu-
defined as the presence of IgM, IgA, or high titer IgG in moniae (5%), and, less often, H. influenzae (l%), parainflu-
ELISA.6 CMV,S M. pneumoniae, and hepatitis A virus in- enza 1 virus (l%), influenza A virus (1%), influenza B virus
fections were defined as the presence of IgM, and Hae- (l%), adenovirus (l%),herpes simplex virus (l%), and vari-
mophilus influenzae infections as the presence of IgM, IgA, cella zoster virus (1%) (see table 1).The majority of GBS
and IgG antibodies in ELISA. Hepatitis B virus infection patients with positive serology had clinical symptoms of
October 1998 NEUROLOGY 51 1111
Table 1 Zncidence of positive infection serology and symptoms of antecedent infectious illness an GBS patients
_ _ ~
All, Diarrhea, URTI, Other, None,
n = 154, n = 25, n = 68, n = 12, n = 49,
Infection serology n (R) n (5%) n (%) n (%) n (%)
GBS = Guillain-Barre syndrome; URTI = upper respiratory tract infection; other = symptoms other than diarrhea or URTI.
preceding infectious illness (see table 1).Patients with C. attributable proportion of these infections, i.e., the propor-
jejuni infections had diarrhea more often compared with tion of patients that can be attributed to these infections
patients without this infection ( p < 0.001); symptoms of provided they play a causal role in GBS, was calculated as
upper respiratory tract infection (URTI) were less fre- 0.44 (see table 2). Using a multivariate conditional logit
quently found ( p = 0.001). C. jejuni infections were also model for matched case-control data, only infections with
associated with other manifestations of infectious illness C . jejuni, CMV, and EBV appeared to be independently
than diarrhea and URTI, such a s nausea, vomiting, and associated with GBS. Acute infections in the OND controls
abdominal pain. Patients with antecedent CMV infection were not significantly associated with any of the diagnostic
frequently had URTI and other manifestations of infection categories. The OND patients with positive serology had
such as nausea, fever, and exanthema, but none had diar- MS (n = 8), CIDP (n = 4), other polyneuropathies (n = 7),
rhea. Other manifestations of infection were fever and sore cerebrovascular accident (n = 11, MG (n = l), Friedreich’s
Downloaded from https://www.neurology.org by Kasturba Medical College - MAHE on 4 April 2024
throat in EBV-infected patients and pneumonia and pan- ataxia (n = l),or concussion (n = 1). Differences in the
creatitis in M. pneumoniue-infected patients. In the 49 pa- frequency of C . jejuni, CMV, EBV, and M . pneumoniae
tients who did not report symptoms of antecedent infections between GBS patients and controls could not be
infectious illness, a substantial proportion had positive se- adjusted to differences in their inclusion period because
rology for infections with C. jejuni (29%), CMV (18%),EBV retrospective analysis revealed that the annual incidence
(16%), and M. pneumoniae (4%) (see table 1). The high of these infections did not change significantly in the time
proportion of C. jejuni infections in these patients is in period from 1986 to 1996. In addition, we found no signifi-
accordance with the frequent subclinical course of this in- cant association between the hospital or year of admission
fection. Positive serology for recent infection with parain- and the frequency of specific infections in the groups of
fluenza 2 virus, hepatitis A and B virus, respiratory GBS patients or controls.
syncytial virus, or measles virus could not be demon- Antecedent infections, antiganglioside antibodies, and
strated. None of the infections in GBS patients showed a clinical subgroups. C . jejuni infection was significantly
clear seasonal predominance. associated with antibodies against GM1 and GDlb, and
Positive serology for more than one infection was found CMV infections with antibodies against GM2 (table 3). In-
in 13 (8%)of the GBS patients. Most of these GBS patients terestingly, the only GBS patient with herpes simplex vi-
had positive EBV serology, and were additionally positive rus had high titers of IgG antibodies against LM1, GM3,
for C. jejuni and CMV (n = 21, C. jejuni (n = 2), M. pneu- GDla, GDlb, GTlb, and GQlb. This patient, who had a
moniae (n = 31, CMV (n = 21, and H . influenme (n = 1). pure motor variant of GBS with ophthalmoplegia and hy-
The other patients were positive for C M V and additionally poglossal palsy, needed artificial ventilation and recovered
for C. jejuni (n = I),M . pneumoniae (n = l ) , and influenza to independent locomotion 69 days after IVIg. Infections
A virus (n = 1). with EBV or M . pneumoniae, or any of the other agents,
Antecedent infections in GBS patients compared with were not associated with the tested antiganglioside anti-
controls. Serology for infections with C. jejuni, CMV, bodies. Antibody titers to GM1 and GM2 were also deter-
EBV, and M . pneunzoniae was also performed in the two mined in a subgroup of the OND and healthy controls, but
control groups. Univariate analysis showed that these in- were not found to be associated with the presence of C.
fections were all significantly more frequent in GBS pa- jejuni or CMV infections.6.*
tients compared with matched OND controls (table 2). The Infections with C. jejuni and CMV were each associated
1112 NEUROLOGY 51 October 1998
Table 2 Incidence of recent infections i n GBS patients compared with matched OND controls and healthy subjects
GBS = Guillain-Barre syndrome; OND = other neurologic diseases; OR = odds ratio; CI = confidence interval; - = cannot be
calculated.
with a distinct clinical presentation in GBS, as we previ- time to recovery. Also, the GBS patients with multiple
ously d e ~ c r i b e d .In
~ , ~addition, the case-control study en- positive serology did not significantly differ from the other
abled us to investigate the association tietween these patients with respect to their neurologic presentation.
infections and sex and age. The interaction between sex
and C. jejuni infection was almost significant; the odds Discussion. In the current study, C. jejuni, C M Y ,
ratio (95% confidence interval) in male GBS patients was
EBV, and M. pneumoniae were identified as the most
14.4 (3.1 to 68.1) and in female GBS patients 2.9 (3.1 to
common causes of antecedent infections in GBS.
7.1) ( p = 0.08). The median age of the GBS patients with
EBV infection was 29 years, and with M. pneumoniae in- These infections were found more frequently in GBS
fection 28 years, indicating that they were significantly
patients than in age- and sex-matched controls with
younger than the other GBS patients (median 50 years) OND. Infections with herpes simplex virus, varicella
( p = 0.002 a n d p = 0.001, respectively). Eleven (69%) of zoster virus, influenza A and B virus, parainfluenza
the 16 EBV infected patients had respiratory insufficiency, 1 virus, adenovirus, and H. influenzae were also
which was a significantly higher proportion compared with identified, but their frequency was not significantly
patients with other or no infections (37%) ( p = 0.01). In- higher than in controls. These findings confirm the
Downloaded from https://www.neurology.org by Kasturba Medical College - MAHE on 4 April 2024
fections with these or other micro-organisms were not sig- concept that certain infections are specifically re-
nificantly associated with time to reach nadir, MRC lated to GBS, although a spectrum of infections may
sumscore a t entry and nadir, distribution of weakness, precede the disorder.
cranial nerve involvement, sensory loss, paresthesias, or Previous case-control studies demonstrated C. je-
Table 3 Association between antecedent infections and antiganglioside antibodies i n GBS patients
GM1 20 (41)$ 0
GM2 3 (6) 0
GM3 0 0
GDla 2 (4) 0
GDlb 14 (29)s 0
GTlb 0 0
GQlb 2 (4) 0
LM1 3 (6) 1(14)
GBS patients may indicate that CMV infections in- capacity to induce immune responses to peripheral
duce specific antibodies against antigens present in nerve glycoconjugates, as indicated by their coexis-
these nerves. Anti-GM2 antibodies are associated tence with antibodies to gangliosides and other gly-
with CMV infections in GBS,7,8but the distribution colipids in GBS patients. Moreover, infections with
of GM2 in the human peripheral nerve system is M. pneumoniae, C M V , and EBV are associated with
unknown. Others reported that CMV infections in- cold agglutinins, which preferentially bind to carbo-
duce antibodies against sulfatide and other sulfated hydrate antigens at 4 “ C , a characteristic shared
glycosphingolipids from human peripheral nerves.I9 with antiganglioside a n t i b o d i e ~ .Monoclonal
~~ cold
Interestingly, antisulfatide antibodies were reported agglutinins t o disialylated gangliosides from patients
to be related to sensory nerve involvement in GBS with chronic ataxic neuropathy were found to reduce
and other neuropathies.20 The association between nerve excitability and neurotransmitter release in
CMV infections and antisulfatide antibodies in GBS the mouse hemidiaphragm ~ r e p a r a t i o n Antigan-
.~~
patients, however, has not been established. glioside antibodies in GBS patients with C. jejuni
The current study is the first to demonstrate a infection may be induced by molecular mimicry, as
significantly higher frequency of EBV and M. pneu- ganglioside-like structures were identified in C. je-
moniae infections in GBS patients compared with juni lipopolysaccharides.25In addition, it was demon-
case-matched controls. These frequencies in GBS pa- strated that anti-GM2 antibodies cross-react with
tients are similar to those found by the group of CMV-infected cells? The four GBS-related micro-
Dowling and Cook, i.e., EBV 10% versus 8% and M . organisms also express receptors or toxins that bind
pneumoniae 5% versus 5%.11J0Provided these infec- to carbohydrate antigens and may act as carrier pro-
tions play a role in the pathogenesis of GBS, 9% of teins in the production of of antiglycoconjugate anti-
GBS cases can be attributed to EBV infections, and bodies. C. jejuni produces a toxin that specifically
4% t o infections with M. pneumoniae. These signifi- binds to gangliosides.26 M. pneumoniae binds with
cant but low attributable proportions may explain sialylated carbohydrates from the blood group I anti-
why Winer et a1.,2 in a smaller case-control study, gen and induces antibodies against this s t r u c t ~ r e . ~ 7
were not able to demonstrate an association with one Further research is needed to investigate if molecu-
1114 NEUROLOGY 51 October 1998
lar mimicry with gangliosides or production of combined with methylprednisolone: a pilot study. Ann Neurol
1994;35:749-752.
glycolipid-reactive carrier proteins explains the pre- 14. Asbury AK, Cornblath DR. Assessment of current diagnostic
dominance of these infections in GBS. criteria for Guillain-Barre syndrome. Ann Neurol 1990;
27(suppl):21-24.
References 15. Fleiss JL. Statistical methods for rates and proportions, ch. 8.
New York: John Wiley, 1981.
1. Leneman F. The Guillain-Barre syndrome. Arch Intern Med 16. Breslow NE, Day NE. Statistical methods in cancer research,
1966;118:139-144. vol. 1. The analysis of case-control studies. Lyon, France:
2. Winer JB, Hughes RAC, Anderson MJ, Jones DM, Kangro H, IARC, 1980.
Watkins RPF. A prospective study of acute idiopathic neurop- 17. Ogawa-Goto K, Funamoto N, Ohta Y, Abe T, Nagashima K.
athy. 11. Antecedent events. J Neurol Neurosurg Psychiatry Myelin gangliosides of human peripheral nervous system: an
1988;51:613-618. enrichment of GM1 in the motor nerve myelin isolated from
3. Mishu B, Ilyas AA, Koski CL, e t al. Serologic evidence of cauda equina. J Neurochem 1992;59:1844-1849.
previous Campylobacter jejuni infection in patients with the
18. Boucquey D, Sindic CJM, Lamy M, Delmee M, Tomasi J P ,
Guillain-Barre syndrome. Ann Intern Med K993;118:947-953. Laterre EC. Clinical and serological studies in a series of 45
4. Rees J H , Soudain SE, Gregson NA, Hughes RAC. Campy- patients with Guillain-Barre syndrome. J Neurol Sci 1991;
lobacter jejuni infection in Guillain-Barre syndrome. N Engl
104~56-63.
J Med 1995;333:1374-1379.
5. Rees JH, Gregson NA, Hughes RAC. Anti-ganglioside GM1 19. Ogawa-Goto K, Kubota K, Kurotani A, Abe T. Antibodies
antibodies in Guillain-Barre syndrome and their relationship against sulfated glycosphingolipids of peripheral nerve my-
to Campylobacter jejuni infection. Ann Neurol 1995;38:809- elins detected in patients with human cytomegalovirus infec-
816. tion. J Neuroimmunol 1994;55:55-60.
6. Jacobs BC, van Doorn PA, Schmitz PIM, et al. Campylobacter 20. Van den Berg LH, Lankamp CLAM, de Jager AEJ, et al.
jejuni infections and anti-GM1 antibodies in Guillain-Barre Anti-sulfatide antibodies in peripheral neuropathy. J Neurol
syndrome. Ann Neurol 1996;40:181-187. Neurosurg Psychiatry 1993;56:1164-1168.
7. Irie S,Saito T, Nakamura K, et al. Association of anti-GM2 21. Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I.
antibodies in Guillain-Barre syndrome with acute cytomegalo- Anti-Gal-C antibody in autoimmune neuropathies subsequent
virus infection. J Neuroimmunol 1996;68:19-26. to mycoplasma infection. Muscle Nerve 1995;18:409-413.
8. Jacobs BC, van Doorn PA, Groeneveld JHM, Tio-Gillen AP, 22. Westall FC, Root-Bernstein R. Cause and prevention of
van der Meche FGA. Cytomegalovirus infections and anti- postinfectious and postvaccinal neuropathies in light of a new
GM2 antibodies in Guillain-Barre syndrome. J Neurol Neuro- theory of autoimmunity. Lancet 1986;i:251-252.
surg Psychiatry 1997;62:641- 643. 23. Willison HJ, Veitch J . Immunoglobulin subclass distribution
9. Visser LH, van der Meche FGA, Meulstee J , et al. Cytomega- and binding characteristics of anti-GQlb antibodies in Miller
lovirus infection and Guillain-Barre syndrome: the clinical, Fisher syndrome. J Neuroimmunol 1994;50:159-165.
electrophysiological, and prognostic features. Neurology 1996; 24. Willison HJ, O’Hanlon GM, Paterson GJ, et al. A somatically
47:668-673. mutated human anti-ganglioside antibody that induces exper-
10. Goldschmidt B, Menonna J , Fortunato J , Dowling P, Cook SD. imental neuropathy in mice is encoded by the variable region
Mycoplasma antibody in Guillain-Barre syndrome and other heavy chain gene, V1-18. J Clin Invest 1996;97:1155-1164.
neurological disorders. Ann Neurol 1980;7:108-112. 25. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysac-
11. Dowling PC, Cook SD. Role of infection in Guillain-Barre syn- charide that elicits Guillain-Barr6 syndrome has a GM1
drome: laboratory confirmation of herpesviruses in 41 cases. ganglioside-like structure. J Exp Med 1993;178:1771-1775.
Ann Neurol 1981;9(suppl):44-55. 26. Suzuki S, Kawaguchi M, Mizuno K, Takama K, Yuki N. Im-
12. Van der Meche FGA, Schmitz PIM, the Dutch Guillain-Barre munological properties and ganglioside recognition by Campy-
Study Group. A randomized trial comparing intravenous im- Zobacter jejuni-enterotoxin and cholera toxin. FEMS Immunol
Med Microbiol 1994;8:207-212.
Downloaded from https://www.neurology.org by Kasturba Medical College - MAHE on 4 April 2024